The potential for clinical translation of antibody-targeted nanoparticles in the treatment of acute myeloid leukaemia

Journal of Controlled Release : Official Journal of the Controlled Release Society
Jianfeng GuoCaitriona M O'Driscoll

Abstract

Acute myeloid leukaemia (AML) is a heterogeneous haematopoietic malignancy. Currently, treatment options offer a 5 year survival of <60%. In elderly patients, where the incidence is highest, the survival is much lower. Current standard treatments have significant toxicity and are least well tolerated in older adults, where the need is greatest. Therefore, alternatives are required. Monoclonal antibodies (mAbs), due to the specific targeting to cell surface proteins (i.e. antigens), represent a promising strategy for drug delivery to malignant cells. This concept favours the therapeutic ratio simultaneously by reducing toxicity and increasing efficacy. Although delivery of chemotherapeutics, genes and imaging agents using multifunctional nanoparticles has been substantially explored in treating solid cancers, less information on this approach is available in the case of AML. This review describes the development of antibody-targeted nanoparticulate drug delivery systems, and discusses the barriers to clinical translation in the treatment of AML.

Citations

Feb 11, 2020·Journal of Drug Targeting·Tongtong QiGuimei Lin
Jan 10, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Yukiya TakayamaMakiya Nishikawa
Dec 20, 2019·Dose-response : a Publication of International Hormesis Society·Xiao HuangZhijun Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Cancer Control : Journal of the Moffitt Cancer Center
Mitchell E ReffGary Braslawsky
Nanomedicine
Ralf P FriedrichChristoph Alexiou
© 2022 Meta ULC. All rights reserved